"The REGARD study is remarkable in demonstrating that a monoclonal antibody alone, ramucirumab, added to best supportive care can yield a survival benefit in a treatment-refractory gastric cancer patient population," writes Joseph Chao, MD, of the City of Hope in Duarte, California.

Elderly patients with stage III lung cancer who are not candidates for chemoradiotherapy may benefit from radiation therapy alone, according to a recent study in Lung Cancer.

Accessibility Statement

At MedPage Today, we are committed to ensuring that individuals with disabilities can access all of the content offered by MedPage Today through our website and other properties. If you are having trouble accessing www.medpagetoday.com, MedPageToday's mobile apps, please email legal@ziffdavis.com for assistance. Please put "ADA Inquiry" in the subject line of your email.